07:00 , Aug 4, 2014 |  BC Week In Review  |  Company News

Eli Lilly, Anthera deal

Eli Lilly granted exclusive, worldwide rights to develop and commercialize Sollpura liprotamase to Anthera. Lilly is eligible for undisclosed milestones upon product approval as well as sales milestones and royalties. Anthera said it plans to...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Clinical News

Liprotamase: Development discontinued

On a conference call to discuss its 4Q13 earnings, Eli Lilly disclosed that it discontinued development of liprotamase. In 2011, FDA issued a complete response letter for liprotamase to treat EPI due to cystic fibrosis...
07:00 , Apr 1, 2013 |  BioCentury  |  Finance

Back for thirds

Despite having only two exits under its belt since inception in 2007,...
01:24 , Jan 9, 2013 |  BC Extra  |  Company News

Shire to acquire Orphan company Lotus Tissue Repair

Shire plc (LSE:SHP; NASDAQ:SHPG) will acquire Lotus Tissue Repair Inc. (Cambridge, Mass.) for an undisclosed upfront payment, plus milestones. Shire will gain Lotus Tissue's lead product, a preclinical recombinant form of human collagen Type VII...
08:00 , Nov 21, 2011 |  BioCentury  |  Finance

Alnara to Allena

Alnara to Allena Investors hope Allena Pharmaceuticals Inc. will get an oral enzyme through early Phase II data with the $15 million series A round it raised last week. The biotech was founded by two...
01:33 , Nov 17, 2011 |  BC Extra  |  Financial News

Former Alnara execs launch Allena with $15M

Newco Allena Pharmaceuticals Inc. (Newton, Mass.) raised $15 million in a series A round led by Bessemer Venture Partners; Frazier Healthcare; and Third Rock Ventures. Allena is developing non-systemic oral protein therapeutics to treat metabolic...
07:00 , Apr 25, 2011 |  BC Week In Review  |  Clinical News

Liprotamase regulatory update

FDA issued a complete response letter for Eli Lilly's liprotamase to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), chronic pancreatitis, pancreatectomy or other conditions. The agency asked the company to conduct an...
08:00 , Jan 24, 2011 |  BioCentury  |  Product Development

Really insufficient

Solpura liprotamase for exocrine pancreatic insufficiency could be the poster child for why it's a good idea to run head-to-head clinical trials. If those had been done early on, the product might now be on...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Clinical News

Solpura liprotamase regulatory update

FDA's Gastrointestinal Drugs Advisory Committee voted 7-4, with 1 abstention, against recommending approval of Eli Lilly's Solpura liprotamase to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), chronic pancreatitis, pancreatectomy or other conditions....
01:27 , Jan 13, 2011 |  BC Extra  |  Top Story

FDA panel rebuffs Solpura

FDA's Gastrointestinal Drugs Advisory Committee voted 7-4, with one abstention, against recommending approval of Solpura liprotamase from Eli Lilly and Co. (NYSE:LLY) to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), chronic pancreatitis,...